Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • AT1 cells in bronchopulmonary dysplasia
  • The AT1 matrisome in development
  • Next steps and conclusions
  • Footnotes
  • References
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Commentary Open Access | 10.1172/JCI178562

Disrupted TGF-β signaling: a link between bronchopulmonary dysplasia and alveolar type 1 cells

Rongbo Li

Department of Pediatrics, University of California, San Diego, La Jolla, California, USA.

Address correspondence to: Rongbo Li, 9500 Gilman Dr. MC 0766, La Jolla, California 92093, USA. Phone: 858.246.2067; Email: rol043@health.ucsd.edu.

Find articles by Li, R. in: PubMed | Google Scholar

Published March 15, 2024 - More info

Published in Volume 134, Issue 6 on March 15, 2024
J Clin Invest. 2024;134(6):e178562. https://doi.org/10.1172/JCI178562.
© 2024 Li This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published March 15, 2024 - Version history
View PDF

Related article:

TGF-β controls alveolar type 1 epithelial cell plasticity and alveolar matrisome gene transcription in mice
Danielle A. Callaway, … , Benjamin A. Garcia, Edward E. Morrisey
Danielle A. Callaway, … , Benjamin A. Garcia, Edward E. Morrisey
TGFβ mediates alveolar type 1 cell spreading, identity, and matrisome expression during late lung development, which, if perturbed, may predispose to disease including bronchopulmonary dysplasia.
Research Article Pulmonology

TGF-β controls alveolar type 1 epithelial cell plasticity and alveolar matrisome gene transcription in mice

  • Text
  • PDF
Abstract

Premature birth disrupts normal lung development and places infants at risk for bronchopulmonary dysplasia (BPD), a disease disrupting lung health throughout the life of an individual and that is increasing in incidence. The TGF-β superfamily has been implicated in BPD pathogenesis, however, what cell lineage it impacts remains unclear. We show that TGFbr2 is critical for alveolar epithelial (AT1) cell fate maintenance and function. Loss of TGFbr2 in AT1 cells during late lung development leads to AT1-AT2 cell reprogramming and altered pulmonary architecture, which persists into adulthood. Restriction of fetal lung stretch and associated AT1 cell spreading through a model of oligohydramnios enhances AT1-AT2 reprogramming. Transcriptomic and proteomic analyses reveal the necessity of TGFbr2 expression in AT1 cells for extracellular matrix production. Moreover, TGF-β signaling regulates integrin transcription to alter AT1 cell morphology, which further impacts ECM expression through changes in mechanotransduction. These data reveal the cell intrinsic necessity of TGF-β signaling in maintaining AT1 cell fate and reveal this cell lineage as a major orchestrator of the alveolar matrisome.

Authors

Danielle A. Callaway, Ian J. Penkala, Su Zhou, Jonathan J. Knowlton, Fabian Cardenas-Diaz, Apoorva Babu, Michael P. Morley, Mariana Lopes, Benjamin A. Garcia, Edward E. Morrisey

×

Abstract

Bronchopulmonary dysplasia (BPD) is a chronic lung disease common in extreme preterm infants and is characterized by alveolar simplification. Current BPD research mainly focuses on alveolar type 2 (AT2) cells, myofibroblasts, and the endothelium. However, a notable gap exists in the involvement of AT1 cells, which constitute a majority of the alveolar surface area. In this issue of the JCI, Callaway and colleagues explored the role of TGF-β signaling in AT1 cells for managing the AT1-to-AT2 transition and its involvement in the integration of mechanical forces with the pulmonary matrisome during development. The findings implicate AT1 cells in the pathogenesis of BPD.

AT1 cells in bronchopulmonary dysplasia

Extreme premature newborns experiencing respiratory distress often need supplemental oxygen and mechanical ventilation, putting them at a high risk of developing bronchopulmonary dysplasia (BPD), characterized by alveolar simplification and disrupted vascular development. Despite advancements in prenatal care improving BPD symptoms, patients often require prolonged ventilatory support and face an elevated risk of subsequent respiratory illnesses, including viral infections (1). Alveolar type 1 (AT1) cells cover over 90% of the alveolar surface area and play a crucial role in efficient gas exchange, owing to their squamous epithelial architecture and close association with the lung microvasculature. However, the precise mechanisms underlying BPD cellular defects, specifically linked to AT1 cells, remain incompletely understood.

In this issue of the JCI, Callaway and colleagues employed a mouse model with an AT1 cell–specific deletion of Tgfbr2 (2). They found that the disruption of TGF-β signaling within AT1 cells during late lung development triggered a cell fate shift from AT1 to AT2 cells, leading to a BPD-like phenotype marked by impaired alveolarization and increased septal thickness. Additionally, they compared the impact of Tgfbr2 loss in AT1 and AT2 cells by inactivating the gene in AT2 cells utilizing the Sftpc-creERT2 driver. Interestingly, unlike the deletion in AT1 cells, mutant lungs lacking Tgfbr2 in AT2 cells exhibited normal AT2-to-AT1 differentiation during development, suggesting that AT2 cells lacking Tgfbr2 did not reprogram during late lung development. However, there was increased AT2 cell proliferation at P5, which led to an increased but nominal proportion of AT2 cells and a minor shift in the ratio of AT2 cells to AT1 cells in Sftpc-creERT2:Tgfbr2 mutant lungs.

Subsequently, Callaway and colleagues utilized a mouse model with oligohydramnios, induced by prenatal reduction of amniotic fluid. This condition resulted in an increased AT1-to-AT2 cell-fate conversion. While the mouse oligohydramnios model and the AT1-specific Tgfbr2 model exhibited similar phenotypes in regard to AT1-to-AT2 cell reprogramming, it appears that the oligohydramnios model may act through distinct mechanisms. This observation arises from the lack of difference between the oligohydramnios treated control and the Hopx-creERT2:Tgfbr2 mutant in terms of AT1-to-AT2 cell reprogramming and mean septal thickness. Oligohydramnios induces a reduction in intraluminal stretch, while loss of Tgfbr2 reduces the capacity of AT1 cells to respond to mechanical cues, leading to conversion towards the AT2 cell phenotype. This study is the first to our knowledge that utilizes AT1 lineage tracing to study oligohydramnios in the context of BPD compared with the previous oligohydramnios mouse model (3). The Callaway et al. findings align with those in their prior publication, which demonstrated that biophysical forces actively preserve AT1 cell identity through Cdc42 and Ptk2-mediated actin remodeling and cytoskeletal strain (4).

The AT1 matrisome in development

To decipher the underlying molecular mechanisms, Callaway and colleagues conducted bulk RNA-Seq and proteomic analyses on neonatal AT1 cells isolated from Hopx-creERT2:Tgfbr2 mutant mice and their heterozygous littermates. The data revealed that loss of Tgfbr2 in AT1 cells led to downregulation of several genes associated with the lung matrisome. The lung matrisome, or lung extracellular matrix (ECM), is composed of collagens, elastin, proteoglycans and glycoproteins. Together, they provide the structural scaffolding for cells and confer the mechanical stability and elastic recoil crucial for proper lung function. Previous research has established that irregularities in the lung matrisome alter lung development and contribute to the progression of conditions like BPD. For instance, in a BPD mouse model induced by lipopolysaccharide (LPS) treatment coupled with hyperoxia, a reduction in fibronectin levels was observed in the lungs (5). Injection of a fibronectin inhibitor arrested alveolar development, suggesting a direct correlation between decreased fibronectin levels and the onset of BPD. Using a single-cell RNA-Seq dataset of the developing mouse lung previously generated by the group (6), Callaway and colleagues compared AT1 cell-enriched lung matrisome components across various development stages. They discovered that genes related to the matrisome exhibit high expression in AT1 cells, which started at E17.5 and remained elevated throughout adulthood. This finding underscores the lifelong importance of AT1 cells as a source for lung matrisome. To validate the findings from bulk RNA-Seq and proteomic analyses, which indicated a downregulation of lung matrisome genes upon Tgfbr2 loss, researchers performed RNA scope and qRT-PCR assays on select lung matrisome genes expressed in AT1 cells. These experiments confirmed decreased expression levels of these genes in Tgfbr2-deficient mice when compared with controls.

To broaden the investigation beyond in vivo observations, researchers isolated AT1 cells from neonatal mice and cultured them in vitro with recombinant TGF-β or the TGF-β inhibitor SB431542. They measured the expression of AT1 ECM components and integrins, which were identified in the in vivo loss-of-function studies. Treatment with TGF-β1 elevated the expression of both Itga5 and Itgb1 compared with the control, whereas groups treated with SB431542 exhibited decreased expression of these integrins. Integrin-mediated cell-ECM interactions are key regulators of cellular behavior, impacting aspects such as spreading, motility, morphology, survival, proliferation, and differentiation. Indeed, AT1 cells obtained from Hopx-creERT2:Tgfbr2 mutant animals displayed notably reduced spreading capacity compared with control cells. Similarly, AT1 cells treated with recombinant TGF-β exhibited a more spread-out appearance compared to the control group, whereas cells treated with SB431542 displayed reduced spreading. These findings indicate that TGF-β acts through regulating the expression of integrins and ECM components in AT1 cells to control AT1 cellular behavior, morphology, and function.

Next steps and conclusions

Single-cell RNA-Seq has emerged as a powerful tool for mapping the transcriptomic landscape of individual cells, providing insights into cellular heterogeneity during lung development and disease. Recent applications of this approach have been instrumental in mapping cell populations within mouse models of hyperoxia-induced BPD (7–9). Findings from these studies highlighted the importance of cellular crosstalk and inflammatory signaling as key drivers of lung injury induced by hyperoxia. Data from single-cell transcriptomic analyses of human BPD lungs will provide further insights into disease pathogenesis and cellular responses. Future research directions should prioritize conducting single-cell transcriptomic analyses in BPD patients. Comparing these findings between human patients and mouse models will provide invaluable insights into potential species-specific differences in disease pathogenesis and cellular responses. The ultimate goal is to unravel the molecular mechanisms underpinning BPD, leading to the development of targeted therapeutic strategies for this devastating disease.

The lung is a complex structure comprising over 35 distinct cell types (10). Active interactions between AT1 cells and other resident lung cell types, such as mesenchymal and endothelial cells, are critical for alveolar development. For instance, AT1 cells predominantly express vascular endothelial growth factor A (VEGFA) (11), and studies have consistently reported lower VEGFA concentrations in infants who later developed BPD (12, 13). Similarly, platelet-derived growth factor subunit A (PDGFA) is primarily secreted by AT1 cells, and reduced PDGFRA expression has been reported in patients with BPD (14). Deletion of PDGFA/PDGFRA signaling in mice leads to simplified alveolar structures (15). In summary, these findings highlight the pivotal role of AT1 cells, acting as a source of ECM that is regulated by TGF-β, in orchestrating lung development. It opens the door to future investigations into the precise mechanisms by which the loss of TGF-β signaling in AT1 cells affects neighboring cell populations. Understanding these intricate intercellular interactions will shed light on how alterations in AT1 cells influence the development and progression of lung pathologies.

Footnotes

Conflict of interest: The author has declared that no conflict of interest exists.

Copyright: © 2024, Li et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: J Clin Invest. 2024;134(6):e178562. https://doi.org/10.1172/JCI178562.

See the related article at TGF-β controls alveolar type 1 epithelial cell plasticity and alveolar matrisome gene transcription in mice.

References
  1. Thebaud B, et al. Bronchopulmonary dysplasia. Nat Rev Dis Primers. 2019;5(1):78.
    View this article via: CrossRef PubMed Google Scholar
  2. Callaway D, et al. TGF-β controls alveolar type 1 epithelial cell plasticity and alveolar matrisome gene transcription. J Clin Invest. 2024;134(6):e172095.
  3. Li J, et al. The strength of mechanical forces determines the differentiation of alveolar epithelial cells. Dev Cell. 2018;44(3):297–312.
    View this article via: CrossRef PubMed Google Scholar
  4. Shiraishi K, et al. Biophysical forces mediated by respiration maintain lung alveolar epithelial cell fate. Cell. 2023;186(7):1478–1492.
    View this article via: CrossRef PubMed Google Scholar
  5. Jin R, et al. IL-33-induced neutrophil extracellular traps degrade fibronectin in a murine model of bronchopulmonary dysplasia. Cell Death Discov. 2020;6:33.
    View this article via: CrossRef PubMed Google Scholar
  6. Zepp JA, et al. Genomic, epigenomic, and biophysical cues controlling the emergence of the lung alveolus. Science. 2021;371(6534):eabc3172.
    View this article via: CrossRef PubMed Google Scholar
  7. Xia S, et al. Neonatal hyperoxia induces activated pulmonary cellular states and sex-dependent transcriptomic changes in a model of experimental bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2023;324(2):L123–L140.
    View this article via: CrossRef PubMed Google Scholar
  8. Scaffa A, et al. Single-cell transcriptomics reveals lasting changes in the lung cellular landscape into adulthood after neonatal hyperoxic exposure. Redox Biol. 2021;48:102091.
    View this article via: CrossRef PubMed Google Scholar
  9. Hurskainen M, et al. Single cell transcriptomic analysis of murine lung development on hyperoxia-induced damage. Nat Commun. 2021;12(1):1565.
    View this article via: CrossRef PubMed Google Scholar
  10. Sun X, et al. A census of the lung: CellCards from LungMAP. Dev Cell. 2021;57(1):112–145.
    View this article via: CrossRef PubMed Google Scholar
  11. Vila Ellis L, et al. Epithelial vegfa specifies a distinct endothelial population in the mouse lung. Dev Cell. 2020;52(5):617–630.
    View this article via: CrossRef PubMed Google Scholar
  12. Lassus P, et al. Vascular endothelial growth factor in human preterm lung. Am J Respir Crit Care Med. 1999;159(5 pt 1):1429–1433.
    View this article via: CrossRef PubMed Google Scholar
  13. Mariduena J, et al. Vascular endothelial growth factor levels and bronchopulmonary dysplasia in preterm infants. J Matern Fetal Neonatal Med. 2022;35(8):1517–1522.
    View this article via: CrossRef PubMed Google Scholar
  14. Popova AP, et al. Reduced platelet-derived growth factor receptor expression is a primary feature of human bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2014;307(3):L231–L239.
    View this article via: CrossRef PubMed Google Scholar
  15. Li R, et al. Pdgfra marks a cellular lineage with distinct contributions to myofibroblasts in lung maturation and injury response. Elife. 2018;7:e36865.
    View this article via: CrossRef PubMed Google Scholar
Version history
  • Version 1 (March 15, 2024): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • AT1 cells in bronchopulmonary dysplasia
  • The AT1 matrisome in development
  • Next steps and conclusions
  • Footnotes
  • References
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts